AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 302 min read$VBIO

Valion Bio, Inc.: Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

Valion Bio (VBIO) and Shear Kershman Labs (SKL) successfully formulated an oral mucosal version of Entolimod, a biologic for radiation protection. This could expand Entolimod's use beyond injectable forms, potentially increasing demand. Valion estimates a 10-40x larger market if the oral formulation is approved, targeting military and emergency personnel. The next step is testing systemic delivery. According to Valion, the injectable program remains a priority.

Original reporting
finanznachrichten.de
Published Sep 30, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VBIO
Neutral
medium confidence
Mentioned
$VBIO
Relevance
5/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$VBIONeutralLow
01

Why it matters

The oral mucosal formulation could broaden the product's use cases and market size if successful.

02

Market read

Milestone may positively influence Valion Bio's valuation but impact is speculative pending further data.

03

What to watch

Funding needs for further studies and competition from other ARS countermeasures.

Relevance 5/10Novelty 6/10Timing: today

Background

Valion Bio is developing Entolimod as a medical countermeasure for acute radiation syndrome, currently administered by injection.

Company-level read

Ticker impact

$VBIONeutralMedium confidence
Context

Valion Bio announced successful formulation of an oral mucosal version of Entolimod, a new development milestone for the company.

Expected impact

potential modest upside as the milestone reduces product risk, but limited immediate price move

Evidence & confidence

Milestone shows progress but no commercial or regulatory approval yet; investors may view it positively but impact is uncertain.

Market effects

Sector

Advances in oral biologic delivery could benefit the broader biotech and medical countermeasure sector.

Regional

Limited to US biotech investors; no immediate regional effect.

Global

Potential interest from defense and emergency response markets worldwide.

Counterpoint

What could challenge this read

The formulation may face significant regulatory and manufacturing hurdles, limiting upside.

Key entities

  • company
    Valion Bio, Inc.

    US-listed biotech developing Entolimod.

  • company
    Shear Kershman Laboratories

    Partner providing the BioViscid delivery platform.

Read at source← All news

Related articles

SEP 30
$VBIOMed

VBIO Stock Jumps As Valion Bio Resets Leadership, Regains Nasdaq Compliance

Valion Bio Inc. (VBIO) stock rose 23.68% after leadership changes and Nasdaq compliance. The company appointed Dean Zikria as interim CEO and Thomas Jensen as board chair. VBIO reported a quarterly loss of $7.1M, with $2.1M in cash and $28.2M in liabilities. The stock's volatility and high-risk profile are driven by its development-stage status and clinical trial news.

stockstotrade.com2 min
SEP 24
$VBIOMed

VBIO Stock Jumps As Valion Bio Resets Leadership And Stabilizes Nasdaq Listing

Valion Bio Inc. (VBIO) shares rose 9.89% on September 24, 2026, following leadership changes and clinical trial success. The company appointed Dean Zikria as interim CEO and Thomas Jensen as board chair. VBIO's stock has been volatile, trading between $2.05 and $3.87 recently. The company reported $2.1M in cash, a net loss of $7.1M, and significant liabilities. Investors are watching for potential partnerships and clinical milestones.

stockstotrade.com3 min
AUG 13
$VBIOMed

Valion Bio, Inc.: Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Valion Bio (Nasdaq:VBIO) said Ukraine’s Ministry of Health accepted its Entolimod dossier for formal review on July 22, 2026, and started a technical assessment with questions on physicochemical characterization for a potential stockpiling supply. The company expects a possible decision as early as Q4 2026, which could enable national registration and potential future government procurement, though no deal is signed.

finanznachrichten.de6 min
AUG 12
$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.

finanznachrichten.de4 min
OCT 13
$ABBVMedAI 8/10

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

AbbVie presented Phase 3 AFFIRM study results showing subcutaneous SKYRIZI® (risankizumab-rzaa) achieved higher endoscopic remission and ulcer-free endoscopy rates in Crohn's disease patients vs. placebo. The data supports FDA approval for a new induction dosing regimen. SKYRIZI is already approved for other immune-mediated diseases.

news.abbvie.com5 min
OCT 13
$WDAYMed

Workday Raises Stakes in AI Race With Major New Bet

Workday (WDAY) shares rose 2% premarket after announcing a partnership with Anthropic to integrate Claude into its Sana AI assistant. The collaboration aims to enable AI-driven actions and approvals in HR and finance workflows, with new features like Sana Concierge for payroll and onboarding tasks. Workday emphasized compliance and governance, with the new services expected to launch in Q1 2027.

finance.yahoo.com5 min